Myeloproliferative neoplasms (MPNs) are clonal hematopoietic cell diseases characterized by gain-of-function mutations in the JAK2, CALR, and MPL genes [1, 2]. CALR is a chaperone protein that resides ...
INCA033989 targets CALR mutations, showing efficacy in engineered cell lines and mouse models of MPNs, without affecting other cells. CALR mutations are significant in JAK2V617F-negative essential ...
Incyte INCY announced that the FDA has granted the Breakthrough Therapy designation to its investigational, first-in-class, mutCALR-targeted monoclonal antibody, INCA033989, to treat patients with ...
NEW HAVEN, Conn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the launch of a new version of its Bloodhound MPN (Myeloproliferative ...
INCA033989 targets mutCALR in ET patients with Type 1 CALR mutations, showing promise in early trials with rapid, durable hematological responses and a favorable safety profile. CALR mutations are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results